Trial Profile
A Multicenter, Multinational, Randomized, Controlled, Assessor Blinded Study, Performed in Subjects With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid Compared to Gel Vehicle and Compared to Standard of Care
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2023
Price :
$35
*
At a glance
- Drugs Bromelains (Primary) ; Bromelains (Primary) ; Collagenase
- Indications Burns
- Focus Registrational; Therapeutic Use
- Acronyms DETECT
- Sponsors MediWound
- 28 Sep 2023 According to a Vericel Corporation media release, results of this study assessing the safety and efficacy of NexoBrid (anacaulase-bcdb) published in the Journal of Burn Care & Research.
- 28 Sep 2023 Results presented in the Vericel Corporation media release.
- 09 May 2023 According to Mediwound media release, BRADA has provided technical assistance and a total funding of $98 million for Nexobird development activities. Amongst the development activities this study is one of the agenda.